In addition to increasing its current good manufacturing practice (cGMP) production capacity, the company will also use the funds to operate its subsidiaries that are advanced novel AAV gene therapy programs, including its lead program, FBX-101, a gene therapy which uses AAV to deliver a functioning copy of the galactosylceramidase (GALC) gene, for the treatment of patients with Krabbe disease.

Forge currently operates a 175,000-sq-ft, cGMP facility in Columbus, OH, that is dedicated to AAV viral vector manufacturing. The company offers end-to-end manufacturing services, including research and toxicology-grade AAV production to support gene therapy programs from preclinical through clinical and commercial stage manufacturing.

The series B financing was led by RA Capital Management.